Dendritic cell therapy -

Lung cancer/lung carcinoma

Conventional treatment & modern immunotherapies

Lung cancer is one of the most common types of cancer worldwide and is divided into two main types:

Non-small cell lung cancer (NSCLC) – approx. 85%
Small cell lung cancer (SCLC) – approx. 15%

The two forms differ significantly in terms of their biological behavior, aggressiveness, and treatment options.

The most important conventional medical therapies are presented below, along with dendritic cell therapy (DCT) as a complementary immunological approach.

Flotte

Classic treatment options for lung cancer

1. Surgery

Surgery is often the most effective treatment for early stages of NSCLC.

The goal is to completely remove the tumor and, if necessary, the affected lymph nodes.

Surgical procedures:

Wedge resection
Segment resection
Lobectomy
Pneumonectomy

Surgery is usually not possible for advanced or metastatic tumors.

2. Radiation therapy

Radiation is used:

when surgery is not possible
for local control
for metastases (e.g., in the brain or bones)
in combination with chemotherapy

Modern techniques (IMRT, SBRT, proton therapy) enable precise and gentle treatment.

3. Chemotherapy

Chemotherapy has a systemic effect throughout the body and is part of many treatment plans.

Typical regimens include:

Platinum-based drugs

Pemetrexed
Taxanes
Chemotherapy is a central component of SCLC treatment in particular, as the tumor grows rapidly and often responds well.

4. Immune checkpoint inhibitors (modern standard therapy)

Immunotherapies are now an established treatment for non-small cell lung cancer.

Drugs used:

Pembrolizumab
Nivolumab
Atezolizumab
Durvalumab

They block certain immune brakes (PD-1/PD-L1) so that T cells can act more actively against tumor cells.

Their effectiveness depends heavily on PD-L1 status, mutations, and tumor type.

5. Targeted therapies

State-of-the-art drugs are available for patients with certain mutations:

EGFR mutation → EGFR inhibitors
ALK/ROS1 translocation → ALK/ROS1 inhibitors
KRAS G12C mutation → KRAS inhibitors
MET, BRAF, RET, etc.

Molecular diagnostics are therefore an important part of lung cancer diagnosis.

6. Combination therapies

Surgery, radiation therapy, immunotherapy, and chemotherapy are often combined to achieve the best possible tumor control.

Medical inquiry

Dendritic cell therapy for lung cancer – a modern immunological approach

Dendritic cell therapy (DZT) is a personalized immunotherapy that specifically activates the body's own immune system.

How it works

Blood sample taken from the patient
Isolation of monocytes
Cultivation and differentiation into dendritic cells
Loading these cells with tumor antigens (e.g., tumor lysate)
Maturation into highly active immune cells
Return to the body via intradermal injections

Dendritic cells present tumor characteristics to T cells, enabling the immune system to target cancer cells more effectively.

DZT as a supplement to conventional cancer therapy

In lung cancer, dendritic cell therapy can be used as a complementary approach:

• DCT + chemotherapy

Chemotherapy reduces tumor mass, DCT strengthens the tumor-directed immune response.

• DCT + immune checkpoint inhibitors

DCT can broaden the spectrum of activated T cells (medical evaluation required).

• DZT + radiation therapy

Radiation therapy releases tumor antigens that DZT can use as a supplement.

• DZT + infusion-based immune system building

e.g., with glutathione, selenium, artesunate, or resveratrol

→ Stabilization of the immune system during stressful therapies.

Therapeutic goals of DZT in lung cancer

Activation of specific T cells against tumor cells

Improvement of immune surveillance
Support of conventional therapies
Stabilization of general condition
Strengthening of the body's own defenses during stressful phases of therapy
The response is individual and depends on the type of tumor, stage, and immune status.

Crew

Dendritic cell therapy is a patient-specific immunological approach.

No promises of a cure are made.